Design, mechanism, delivery and therapeutics of canonical and Dicer-substrate siRNA

Maria Abdul Ghafoor Raja, Haliza Katas, Muhammad Wahab Amjad

Research output: Contribution to journalReview article

Abstract

Upon the discovery of RNA interference (RNAi), canonical small interfering RNA (siRNA) has been recognized to trigger sequence-specific gene silencing. Despite the benefits of siRNAs as potential new drugs, there are obstacles still to be overcome, including off-target effects and immune stimulation. More recently, Dicer substrate siRNA (DsiRNA) has been introduced as an alternative to siRNA. Similarly, it also is proving to be potent and target-specific, while rendering less immune stimulation. DsiRNA is 25–30 nucleotides in length, and is further cleaved and processed by the Dicer enzyme. As with siRNA, it is crucial to design and develop a stable, safe, and efficient system for the delivery of DsiRNA into the cytoplasm of targeted cells. Several polymeric nanoparticle systems have been well established to load DsiRNA for in vitro and in vivo delivery, thereby overcoming a major hurdle in the therapeutic uses of DsiRNA. The present review focuses on a comparison of siRNA and DsiRNA on the basis of their design, mechanism, in vitro and in vivo delivery, and therapeutics.

Original languageEnglish
JournalAsian Journal of Pharmaceutical Sciences
DOIs
Publication statusPublished - 1 Jan 2019

Fingerprint

Small Interfering RNA
Therapeutics
Ribonuclease III
Gene Silencing
Therapeutic Uses
RNA Interference
Nanoparticles
Cytoplasm
Nucleotides
Pharmaceutical Preparations

Keywords

  • Drug delivery system
  • Gene carrier
  • Gene silencing
  • Non-viral vector
  • Polymeric nanoparticles
  • RNA interference

ASJC Scopus subject areas

  • Pharmacology
  • Pharmaceutical Science

Cite this

Design, mechanism, delivery and therapeutics of canonical and Dicer-substrate siRNA. / Raja, Maria Abdul Ghafoor; Katas, Haliza; Amjad, Muhammad Wahab.

In: Asian Journal of Pharmaceutical Sciences, 01.01.2019.

Research output: Contribution to journalReview article

@article{ba0dfbd3eed64c4ea5a2d743f6b3c011,
title = "Design, mechanism, delivery and therapeutics of canonical and Dicer-substrate siRNA",
abstract = "Upon the discovery of RNA interference (RNAi), canonical small interfering RNA (siRNA) has been recognized to trigger sequence-specific gene silencing. Despite the benefits of siRNAs as potential new drugs, there are obstacles still to be overcome, including off-target effects and immune stimulation. More recently, Dicer substrate siRNA (DsiRNA) has been introduced as an alternative to siRNA. Similarly, it also is proving to be potent and target-specific, while rendering less immune stimulation. DsiRNA is 25–30 nucleotides in length, and is further cleaved and processed by the Dicer enzyme. As with siRNA, it is crucial to design and develop a stable, safe, and efficient system for the delivery of DsiRNA into the cytoplasm of targeted cells. Several polymeric nanoparticle systems have been well established to load DsiRNA for in vitro and in vivo delivery, thereby overcoming a major hurdle in the therapeutic uses of DsiRNA. The present review focuses on a comparison of siRNA and DsiRNA on the basis of their design, mechanism, in vitro and in vivo delivery, and therapeutics.",
keywords = "Drug delivery system, Gene carrier, Gene silencing, Non-viral vector, Polymeric nanoparticles, RNA interference",
author = "Raja, {Maria Abdul Ghafoor} and Haliza Katas and Amjad, {Muhammad Wahab}",
year = "2019",
month = "1",
day = "1",
doi = "10.1016/j.ajps.2018.12.005",
language = "English",
journal = "Asian Journal of Pharmaceutical Sciences",
issn = "1818-0876",
publisher = "Hong Kong Asiamed Publishing House",

}

TY - JOUR

T1 - Design, mechanism, delivery and therapeutics of canonical and Dicer-substrate siRNA

AU - Raja, Maria Abdul Ghafoor

AU - Katas, Haliza

AU - Amjad, Muhammad Wahab

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Upon the discovery of RNA interference (RNAi), canonical small interfering RNA (siRNA) has been recognized to trigger sequence-specific gene silencing. Despite the benefits of siRNAs as potential new drugs, there are obstacles still to be overcome, including off-target effects and immune stimulation. More recently, Dicer substrate siRNA (DsiRNA) has been introduced as an alternative to siRNA. Similarly, it also is proving to be potent and target-specific, while rendering less immune stimulation. DsiRNA is 25–30 nucleotides in length, and is further cleaved and processed by the Dicer enzyme. As with siRNA, it is crucial to design and develop a stable, safe, and efficient system for the delivery of DsiRNA into the cytoplasm of targeted cells. Several polymeric nanoparticle systems have been well established to load DsiRNA for in vitro and in vivo delivery, thereby overcoming a major hurdle in the therapeutic uses of DsiRNA. The present review focuses on a comparison of siRNA and DsiRNA on the basis of their design, mechanism, in vitro and in vivo delivery, and therapeutics.

AB - Upon the discovery of RNA interference (RNAi), canonical small interfering RNA (siRNA) has been recognized to trigger sequence-specific gene silencing. Despite the benefits of siRNAs as potential new drugs, there are obstacles still to be overcome, including off-target effects and immune stimulation. More recently, Dicer substrate siRNA (DsiRNA) has been introduced as an alternative to siRNA. Similarly, it also is proving to be potent and target-specific, while rendering less immune stimulation. DsiRNA is 25–30 nucleotides in length, and is further cleaved and processed by the Dicer enzyme. As with siRNA, it is crucial to design and develop a stable, safe, and efficient system for the delivery of DsiRNA into the cytoplasm of targeted cells. Several polymeric nanoparticle systems have been well established to load DsiRNA for in vitro and in vivo delivery, thereby overcoming a major hurdle in the therapeutic uses of DsiRNA. The present review focuses on a comparison of siRNA and DsiRNA on the basis of their design, mechanism, in vitro and in vivo delivery, and therapeutics.

KW - Drug delivery system

KW - Gene carrier

KW - Gene silencing

KW - Non-viral vector

KW - Polymeric nanoparticles

KW - RNA interference

UR - http://www.scopus.com/inward/record.url?scp=85063646579&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85063646579&partnerID=8YFLogxK

U2 - 10.1016/j.ajps.2018.12.005

DO - 10.1016/j.ajps.2018.12.005

M3 - Review article

AN - SCOPUS:85063646579

JO - Asian Journal of Pharmaceutical Sciences

JF - Asian Journal of Pharmaceutical Sciences

SN - 1818-0876

ER -